Randomised study: effects of the 5-HT4 receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis.

Victor G ChedidJustin BrandlerKayla ArndtPriya VijayvargiyaXiao Jing WangDuane BurtonW Scott HarmsenJenifer SiegelmanChunlin ChenYinzhong ChenCristina AlmansaGeorge DukesMichael Camilleri

Published in: Alimentary pharmacology & therapeutics (2021)

I.V. felcisetrag significantly accelerated gastric, small bowel and colonic transit in patients with gastroparesis, and should be further evaluated for short-term treatment of gastric and intestinal motility disorders. ClinicalTrials.gov #NCT03281577.

Keyphrases

small bowel
clinical trial
double blind
open label
placebo controlled
study protocol
biofilm formation
escherichia coli
phase iii
pseudomonas aeruginosa
ulcerative colitis
replacement therapy